Neuroscience 2021

At Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. We offer a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic ... and proteomic research, and food safety. We accelerate reliable answers while simplifying complexity and deliver certainty with a seamless experience.

Envigo provides the broadest range of research models and related services to the pharmaceutical and biotechnology industries, government, academia, and other life science organizations. As the largest organization that is solely dedicated to providing research models and related ... products and services, we are committed to helping researchers realize the full potential of their critical R&D projects as we fulfill our mission to work together to build a healthier and safer world. Read more at envigo.com

NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications ... NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna®, its first in vitro diagnostic product for prognosis of early stage breast cancer. Organizations performing cancer research, biomarker validation and screening, and next-generation sequencing validation are rapidly adopting the nCounter® Analysis System. By providing simple, multiplexed digital profiling of single molecules, the NanoString platform represents a natural, digital downstream companion to next-generation sequencing and enables researchers to embark on studies that were previously inconceivable. Leading researchers and institutions are finding that NanoString's nCounter system provides the ideal platform on which to validate their discoveries and translate them into clinically useful diagnostic assays. The nCounter system is uniquely positioned to support translational research because it provides more reproducible results than methods requiring amplification, and generates high-quality data from the difficult sample types common in clinical research, including Formalin-Fixed Paraffin-Embedded (FFPE) tissues. In addition to continuing to extend the applications for the nCounter system in the discovery, target validation and routine testing segments of the genomics research market, the company's goal is to become the platform of choice for diagnostic testing based on multiplexed gene signatures that can be offered in hospitals and pathology laboratories worldwide, following appropriate regulatory approvals. These two synergistic areas of business focus provide researchers with a seamless transition from discovery to diagnostics.

At Atlas Antibodies we have a very clear mission: To provide our customers with advanced research reagents targeting all human proteins. The Human Protein Atlas (HPA) project released the first version of a complete tissue-based map of human protein expression using antibodies in ... November 2014. In close partnership with the HPA project, we continue to develop advanced antibodies and advanced reagents for Mass Spectrometry (MS)-based quantitative proteomics. Of the possible 20,000 protein coding genes in the human body we already have over 18,000 antibodies covering 15,000 gene products and an additional 19,000 protein quantification MS-standards representing 13,000 protein targets.

PLOS is a nonprofit, Open Access publisher empowering researchers to accelerate progress in science and medicine by leading a transformation in research communication. We've been breaking boundaries since our founding in 2001. PLOS journals propelled the movement for OA ... alternatives to subscription journals. We established the first multi-disciplinary publication inclusive of all excellent research regardless of novelty or impact, and demonstrated the importance of open data availability. As Open Science advances, we continue to experiment to provide more opportunities, choice, and context for readers and researchers.

OriGene Technologies was founded as a research tool company focused on the creation of the large commercial collection of full-length human cDNAs in a standard expression vector. The availability of the complete human genome sequence and the subsequent development of genome-based ... tools have enabled the identification of relevant drug targets through system biology approaches. OriGene's vision is to prepare comprehensive, genome wide research tools and technology platforms to enable scientists to study complete biological pathways, thus enabling a better understanding of disease mechanisms including cancer and stem cell research. OriGene Technologies uses high-throughput, genome wide approach to develop products for pharmaceutical, biotechnology, and academic research. Our flagship product is the cDNA clone collection, a searchable gene bank of over 40,000 human full-length TrueClone cDNA collection and over 35,000 human TrueORF cDNA clones. From our TrueORF cDNA clones, we have developed the broad offering of full length human proteins, such as "MVPro" proteins, expressed in mammalian cells, ideal for functional studies. In 2010, OriGene initiated the TrueMAB™ project to develop mouse monoclonal antibodies against protein antigens with the goal to develop protein assays for every human protein. OriGene also began the TrueRAB™ project to develop single B cell cloning technology for the generation of recombinant rabbit monoclonal antibodies with high affinity and against targets with low immunogenicity in mouse system. In addition, OriGene offers different gene expression products such as TissueScan cancer tissue qPCR arrays and tissue biorepository for biomarker discovery and validation OriGene is committed to its mission to be "Your Gene Company", in supplying everything a researcher needs for gene based research. For more information, please visit us at www.origene.com

BioLegend enables life science discovery from research to cure by providing world-class quality biological reagents and tools at an outstanding value, with highly acclaimed customer service and technical support. Guided by our award-winning entrepreneurial leadership team, we ... have secured loyal customers and trusted partners at the world's premier research institutions, biotechnology and pharmaceutical companies. Our scientists collaboratively develop cutting-edge research and diagnostic products, establishing BioLegend as a global leader in immunology, cancer research, neuroscience, cell biology, proteogenomics, stem cells, and other emerging sectors. Recognized as one of the fastest growing life science companies, BioLegend transforms the boundaries of innovation for basic science and medical researchers world-wide. To learn more, visit www.biolegend.com

Asuragen is a molecular diagnostic product company changing the way patients are treated in genetics and oncology. Asuragen's diagnostic systems, composed of proprietary chemistry and software, deliver powerful answers using broadly installed instrument platforms. They are simple ... to adopt and expand the ability to serve patients. Asuragen is a product foundry rapidly and efficiently addressing current and emerging clinical needs, including cancer diagnosis and monitoring, reproductive health and aging, serving laboratories across a patient's lifespan with its best-in-class diagnostic tests. For more information, visit www.asuragen.com.

Miltenyi Biotec delivers solutions that advance biomedical research and cellular therapy. As the SARS-CoV-2 pandemic continues to take its toll around the world, Miltenyi Biotec stands committed to helping our customers navigate through this challenging time. With over 30 years ... of expertise in immunology and with our dedicated commitment to technological innovation, we offer robust research solutions, cell-specific products, and time- and material-saving tools and protocols that are ideally suited for working with infectious materials.

Micro refers to our expertise in microfluidics and GEM stands for Genes, Enzymes, and Microbes. MicroGEM is putting rapid diagnostic capabilities where they're needed most - whether it's a farmer's field in Uganda to diagnose cassava mosaic virus or the depths of the Pacific ... Ocean to rapidly sample and analyze water pathogens. We are democratizing molecular biology - bringing molecular biology techniques out of conventional, highly skilled laboratories to the point-of-need where they can be used by anyone to solve complex biological problems. Our temperature-driven, enzymatic approach to nucleic acid extractions is the first step. We're combining these rapid extraction capabilities with our expertise in microfluidics to develop next-generation point-of-need solutions.